CoLucid Pharmaceuticals Inc. (Nasdaq: CLCD) will be acquired by Eli Lilly and Co. (Nasdaq: LLY) for a premium of approximately $960 million in cash. Shares of CoLucid Pharmaceuticals leaped $11.35 to close at $46.25 while Eli Lilly stock added 68 cents to close at $77.53.